


ASTRAZENECA PLC

Interim Accounts

10 NOVEMBER 2000



Registered number : 2723534

ASTRAZENECA PLC**PROFIT AND LOSS ACCOUNT**
for the 315 days ended 10 November 2000

	Notes	315 days ended 10 Nov \$m	Year ended 31 Dec 1999 \$m
Turnover		-	-
Operating costs		-	(7)
Operating loss		-	(7)
Income from shares in subsidiary undertakings		2,438	2,034
Profit on ordinary activities before merger costs and interest		2,438	2,027
Merger costs		-	(70)
Net interest and exchange gains/losses	2	(247)	(76)
Profit on ordinary activities before taxation		2,191	1,881
Taxation		42	-
Net profit for the period/year		2,233	1,881
Dividends to Shareholders	3	(406)	(1,601)
Profit retained for the period/year		1,827	280

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
for the 315 days ended 10 November 2000

	315 days ended 10 Nov \$m	Year ended 31 Dec 1999 \$m
Net profit for the period/year	2,233	1,881
Unrealised gain on transfer of investment in Astra AB	-	32,839
Exchange (loss)/gain on receivable arising on transfer of investment in Astra AB	(3,478)	79
Revaluation of investments	2,116	-
Total recognised gains and losses relating to the period/year	871	34,799

ASTRAZENECA PLC

BALANCE SHEET


as at 10 November 2000

	Notes	10 Nov 2000 \$m	31 Dec 1999 \$m
Fixed assets			
Tangible fixed assets		-	-
Fixed asset investments	4	8,853	905
		8,853	905
Current assets			
Stocks		-	-
Debtors		28,164	37,957
Cash and short-term investments		-	-
		28,164	37,957
Total assets		37,017	38,862
Creditors due within one year			
Short-term borrowings		-	-
Other creditors		(26)	(2,015)
		(26)	(2,015)
Net current assets		28,138	35,942
Total assets less current liabilities		36,991	36,847
Creditors due after more than one year			
Loans		(590)	(590)
		(590)	(590)
Provisions for liabilities and charges		-	-
Net assets		36,401	36,257
Capital and reserves			
Called-up share capital	5	442	444
Share premium account	6	233	202
Capital redemption reserve	6	3	1
Other reserves	6	4,355	2,239
Profit and loss account	6	31,368	33,371
Shareholders' funds - equity interests		36,401	36,257

The non-statutory financial statements on pages 1 to 6 were approved by the Board of Directors on 10 November 2000 and signed on its behalf by:



Tom McKillop
Director



Jonathan Symonds
Director

ASTRAZENECA PLC

NOTES RELATING TO THE INTERIM ACCOUNTS

1 Basis of presentation of financial information

These AstraZeneca PLC accounts have been prepared by the directors to support a proposed dividend in specie in connection with the demerger of Syngenta AG. They have been properly prepared in accordance with the Companies Act 1985, subject only to matters which are not material for determining, by reference to items mentioned in s270 of the Act, whether the proposed distribution would contravene the requirements of the Act.

The statements are unaudited and do not comprise the statutory accounts of the Group. Statutory accounts for AstraZeneca PLC for the year ended 31 December 1999 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

The interim accounts are presented in accordance with the accounting policies set out in the 1999 annual accounts, except that the policy on the carrying value of investments has been modified. These are generally held at cost. However, the investment in Syngenta AG is held at a valuation which represents the global offer price of shares in that company determined by Credit Suisse First Boston and UBS Warburg as at 4 pm on the 10 November 2000. The directors believe this to be an appropriate basis as the global offer price represents the fair value of the investment in Syngenta AG as at 4 pm on the 10 November 2000 prior to demerger, and as such represents the fair value of the proposed dividend in specie. As the purpose of these accounts is to support the proposed dividend in specie, the directors feel that showing the investment at cost would not represent a true and fair view.

The impact of the revaluation has been to increase other reserves by \$2,116m (1999 - nil)

2 Net interest and exchange gains/losses

	315 days ended 10 Nov 2000 \$m	Year ended 31 Dec 1999 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(36)	(48)
External interest payable	-	-
Net exchange gains/losses	(247)	(76)
	(283)	(124)
Interest receivable and similar income		
Receivable from subsidiary undertakings	36	48
	36	48
Net interest and exchange gains/losses	(247)	(76)

NOTES RELATING TO THE INTERIM ACCOUNTS (continued)

3 Dividends to Shareholders

	315 days ended 10 Nov 2000 cents per 25c Share	Year ended 31 Dec 1999 cents per 25c Share	315 days ended 10 Nov 2000 \$m	Year ended 31 Dec 1999 \$m
Payment of Astra 1998 Final Dividend	-	-	-	359
1st interim	23c	23c	406	408
2nd interim/final	-	47c	-	834
	23c	70c	406	1,601

4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
Cost or valuation			
At beginning of period	314	591	905
Additions before revaluation	6,430	-	6,430
Disposals	(598)	-	(598)
Revaluation of Syngenta AG to Global Offer Price	2,116	-	2,116
Cost or valuation and net book value at end of period	8,262	591	8,853

5 Called-up share capital

	Authorised 10 Nov 2000 \$m	Allotted, called-up and fully paid 10 Nov 2000 \$m	1999 \$m
Ordinary Shares (\$0.25 each)	444	442	444
Unissued Ordinary Share (\$0.25 each)	156	-	-
Redeemable Preference Shares	-	-	-
	600	442	444

The movements in share capital during the period can be summarised as follows:

	No of shares (million)	\$m
At beginning of year	1,775	444
Repurchase of shares	(9)	(2)
At end of period	1,766	442

NOTES RELATING TO THE INTERIM ACCOUNTS (continued)

6 Reserves

	Share Premium Account \$m	Capital Redemption Reserve \$m	Other Reserves \$m	Profit and Loss Account \$m	Total 2000 \$m	Total 1999 \$m
At beginning of period	202	1	2,239	33,371	35,813	2,492
Retained profit for the period	-	-	-	1,827	1,827	280
Issue of shares	31	-	-	-	31	148
Unrealised gain on transfer of investment in Astra AB	-	-	-	-	-	32,839
Exchange (loss)/gain on receivable arising on transfer of investment in Astra AB	-	-	-	(3,478)	(3,478)	79
Revaluation of investments	-	-	2,116	-	2,116	-
Repurchase of shares	-	-	-	(350)	(350)	(182)
Transfer to capital redemption	-	2	-	(2)	-	-
Redenomination of share capital	-	-	-	-	-	157
At end of period	233	3	4,355	31,368	35,959	35,813

In 1999 the Company sold its investment in Astra AB to a subsidiary, resulting in a gain of \$32,839m which was taken to reserves via the statement of total recognised gains and losses. This gain, which represents an unrealised profit, will be realised as the underlying receivable is settled in cash. The exchange loss on the underlying receivable for the period ended 10 November 2000 of \$3,478m (year ended 31 December 1999: gain of \$79m) has also been taken to reserves via the statement of total recognised gains and losses. The gain on the revaluation of the investment in Syngenta AG of \$2,116m has been taken to reserves via the statement of total recognised gains and losses. On the distribution in specie of the investment in Syngenta AG that the directors intend proposing on the basis of these interim accounts, that unrealised gain may be treated as realised in determining the lawfulness of that distribution. The balance on the profit and loss account at 10 November 2000 includes \$29,440m which is not available for distribution (31 December 1999 - \$32,918m). Included in other reserves is the special reserve of \$157m, arising on the redenomination of share capital, and the revaluation reserve of \$2,116m. Of the remaining balance on other reserves, \$442m is distributable.

NOTES RELATING TO THE INTERIM ACCOUNTS (continued)

7 Reconciliation of Movements in Shareholders' Funds

	315 days ended 10 Nov 2000 \$m	Year ended 31 Dec 1999 \$m
Net profit for the financial period	2,233	1,881
Dividends	(406)	(1,601)
	1,827	280
Other recognised gains and losses	(1,362)	32,918
Issues of AstraZeneca Ordinary Shares	31	356
Repurchase of AstraZeneca Ordinary Shares	(352)	(183)
Net addition to shareholders' funds	144	33,371
Shareholders' funds at beginning of period/year	36,257	2,886
Shareholders' funds at end of period/year	36,401	36,257